ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACADIA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$19.80+0.68 (+3.56%)
Close on Oct 19, 2026
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- Dividend yield
- –
ACADIA PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | – | – | – | – | $223.81M | $124.90M | $17.33M | – | – |
| Product and Service, Other [Member] | – | – | – | – | – | – | $4.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Acadia Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.